amlodipine has been researched along with Stroke in 75 studies
Amlodipine: A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.
amlodipine : A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.
Stroke: A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hyperhomocysteinemia with hypertension can synergistically increase the risk of stroke." | 9.69 | Combined use of amlodipine and folic acid are significantly more efficacious than amlodipine alone in lowering plasma homocysteine and blood pressure among hypertensive patients with hyperhomocysteinemia and intolerance to ACEI: A multicenter, randomized, ( Bao, H; Chen, G; Cheng, X; Cheng, Z; Cui, Y; Ding, C; Hu, L; Huang, X; Huo, Y; Li, P; Qin, X; Sheng, C; Song, D; Tang, G; Wang, J; Wang, X; Wang, Z; Yao, C; Zhang, J, 2023) |
| "The aim of this study was to compare the efficacy and safety of lercanidipine and amlodipine in the treatment of hypertensive patients with acute cerebral ischemic stroke." | 9.20 | Effects of lercanidipine versus amlodipine in hypertensive patients with cerebral ischemic stroke. ( Cao, TS; Huynh, VM; Tran, VH, 2015) |
| "This study was conducted to compare the BP-lowering and diurnal BP variation effects of amlodipine and losartan on acute stroke patients." | 9.17 | Comparison of the effects of amlodipine and losartan on blood pressure and diurnal variation in hypertensive stroke patients: a prospective, randomized, double-blind, comparative parallel study. ( Hong, YH; Kwon, HM; Lee, YS; Lim, JS; Nam, H; Shin, JW, 2013) |
| "In the present quantitative overview of outcome trials, we investigated the efficacy of amlodipine or angiotensin receptor blockers in the prevention of stroke and myocardial infarction in patients with hypertension, coronary artery disease, or diabetic nephropathy." | 8.84 | Prevention of stroke and myocardial infarction by amlodipine and Angiotensin receptor blockers: a quantitative overview. ( Franklin, SS; Li, Y; Safar, M; Wang, JG, 2007) |
| "In newly diagnosed patients with hypertension, lercanidipine was superior to nifedipine in the six-year period when the analyzed endpoint was stroke." | 7.85 | Long-term outcomes of lercanidipine versus other calcium channel blockers in newly diagnosed hypertension: a nationwide cohort study. ( Cheng, KC; Cheng, KH; Cheng, KY; Lai, WT; Lee, CW; Yang, YH, 2017) |
| "The current study investigated the efficacy of losartan and amlodipine in protecting spontaneously hypertensive stroke-prone (SHRSP) rats against the risk of stroke." | 7.83 | Prehypertensive treatment with losartan, however not amlodipine, leads to long-term effects on blood pressure and reduces the risk of stroke in spontaneously hypertensive stroke-prone rats. ( He, D; Lin, J; Zhang, L, 2016) |
| "The vascular protective effects of placebo, candesartan (1 mg kg(-1) per day) monotherapy, candesartan (1 mg kg(-1) per day) and amlodipine (1 mg kg(-1) per day) combination therapy, and candesartan (1 mg kg(-1) per day) and hydrochlorothiazide (HCTZ) (10 mg kg(-1) per day) combination therapy for 2 weeks were compared in stroke-prone, spontaneously hypertensive rats." | 7.77 | Candesartan and amlodipine combination therapy provides powerful vascular protection in stroke-prone spontaneously hypertensive rats. ( Jin, D; Miyazaki, M; Sakonjo, H; Shimosato, T; Takai, S, 2011) |
| " In this study, we investigated whether amlodipine protects against the reduction in bone density in stroke-prone spontaneously hypertensive rats (SHR-sp)." | 7.76 | Protective effect of amlodipine against osteoporosis in stroke-prone spontaneously hypertensive rats. ( Ando, H; Fujimura, A; Ishikawa, E; Liu, Y; Maekawa, T; Motosugi, Y; Tsuruoka, S; Ushijima, K, 2010) |
| "To report a case of angioedema likely associated with amlodipine administration in a patient with a right thalamic hemorrhagic stroke." | 7.75 | Probable amlodipine-induced angioedema. ( Irvine, E; Rabinovich, M; Southward, J, 2009) |
| "To test the effects of atenolol and amlodipine, either alone or in combination, on blood pressure, blood pressure variability (BPV), baroreflex sensitivity (BRS), and the prevalence of stroke in stroke-prone spontaneously hypertensive rats (SHR-SP)." | 7.74 | Effects of combination therapy with atenolol and amlodipine on blood pressure control and stroke prevention in stroke-prone spontaneously hypertensive rats. ( Cai, GJ; Ling, G; Liu, AJ; Liu, JG; Shen, FM; Su, DF, 2007) |
| "This study investigated the effects of amlodipine, an L-type calcium channel blocker, on stroke size after focal brain ischemia in apolipoprotein E-deficient (ApoE KO) mice." | 7.73 | Amlodipine treatment reduces stroke size in apolipoprotein E-deficient mice. ( Chen, R; Horiuchi, M; Ide, A; Iwai, M; Iwanami, J; Mogi, M; Tsukuda, K; Yoshii, T, 2006) |
| "Excess salt, via oxidative stress, accelerates stroke, and angiotensin II, via AT1 receptor, plays a pivotal role in brain superoxide production of SHRSP by excess salt." | 7.73 | Critical role of angiotensin II in excess salt-induced brain oxidative stress of stroke-prone spontaneously hypertensive rats. ( Ioroi, T; Iwao, H; Izumi, Y; Izumiya, Y; Kim-Mitsuyama, S; Tanaka, T; Wanibuchi, H; Yamamoto, E; Zhan, Y, 2005) |
| "In olmesartan-treated patients, CBF significantly increased in the affected and unaffected hemispheres, and CRC increased significantly in the affected hemisphere." | 6.74 | Benefits of the angiotensin II receptor antagonist olmesartan in controlling hypertension and cerebral hemodynamics after stroke. ( Kawahira, K; Matsumoto, S; Miyata, R; Shimodozono, M, 2009) |
| "Hyperhomocysteinemia with hypertension can synergistically increase the risk of stroke." | 5.69 | Combined use of amlodipine and folic acid are significantly more efficacious than amlodipine alone in lowering plasma homocysteine and blood pressure among hypertensive patients with hyperhomocysteinemia and intolerance to ACEI: A multicenter, randomized, ( Bao, H; Chen, G; Cheng, X; Cheng, Z; Cui, Y; Ding, C; Hu, L; Huang, X; Huo, Y; Li, P; Qin, X; Sheng, C; Song, D; Tang, G; Wang, J; Wang, X; Wang, Z; Yao, C; Zhang, J, 2023) |
| "Hypertension is considered to be the most important risk factor for stroke, and all forms of hypertension are associated with an increased risk of both ischemic and haemorrhagic stroke." | 5.43 | Significance of BP Control in Reducing Stroke Events: Role of Amlodipine in an Indian Perspective. ( Muruganathan, A; Tiwaskar, M, 2016) |
| "Prehypertension has been associated with adverse cerebrovascular events and brain damage." | 5.40 | Long-term prehypertension treatment with losartan effectively prevents brain damage and stroke in stroke-prone spontaneously hypertensive rats. ( He, DH; Lin, JX; Lin, LM; Ning, RB; Wang, HJ; Xu, CS; Zhang, LM, 2014) |
| "Delirium is a neuropsychiatric syndrome recognized as a marker for increased health care costs, morbidity, mortality, and institutionalization that often complicates acute physical illness in elderly people." | 5.38 | Amlodipine-induced delirium in a patient with ischemic stroke. ( Dikici, S; Kocaman, G; Kocer, A; Ozdem, S, 2012) |
| "Ischemic stroke is a major neurologic disorder and a leading cause of disability and death in the world." | 5.37 | Protection against ischemic stroke damage by synergistic treatment with amlodipine plus atorvastatin in Zucker metabolic rat. ( Abe, K; Deguchi, K; Deguchi, S; Ikeda, Y; Kawai, H; Kurata, T; Matsuura, T; Ohta, Y; Omote, Y; Yamashita, T, 2011) |
| "Stroke is a major neurologic disorder and a leading cause of death in the world." | 5.37 | Synergistic benefit of combined amlodipine plus atorvastatin on neuronal damage after stroke in Zucker metabolic rat. ( Abe, K; Deguchi, K; Deguchi, S; Ikeda, Y; Kawai, H; Liu, N; Liu, W; Matsuura, T; Ohta, Y; Shang, J; Tian, F; Yamashita, T; Zhang, X, 2011) |
| "Amlodipine is a dihydropyridine calcium channel blocker that is widely used for the treatment of hypertensive patients and has an antioxidant effect on vessels in vitro." | 5.33 | Amlodipine-induced reduction of oxidative stress in the brain is associated with sympatho-inhibitory effects in stroke-prone spontaneously hypertensive rats. ( Hirooka, Y; Ito, K; Kimura, Y; Nozoe, M; Sagara, Y; Sunagawa, K, 2006) |
| "Cerebral damage (cerebral edema and blood-brain barrier integrity) was investigated with magnetic resonance imaging twice a week." | 5.31 | Reduction of cerebral injury in stroke-prone spontaneously hypertensive rats by amlodipine. ( Blezer, E; Goldschmeding, R; Joles, J; Koomans, H; Nicolay, K, 2002) |
| "Carotid endarterectomy and medical therapy (aspirin) were shown superior to medical therapy alone for asymptomatic (≥ 60%) carotid stenosis." | 5.20 | Optimal medical treatment versus carotid endarterectomy: the rationale and design of the Aggressive Medical Treatment Evaluation for Asymptomatic Carotid Artery Stenosis (AMTEC) study. ( Boytsov, S; Deev, A; Dupik, N; Kolos, I; Loukianov, M, 2015) |
| "The aim of this study was to compare the efficacy and safety of lercanidipine and amlodipine in the treatment of hypertensive patients with acute cerebral ischemic stroke." | 5.20 | Effects of lercanidipine versus amlodipine in hypertensive patients with cerebral ischemic stroke. ( Cao, TS; Huynh, VM; Tran, VH, 2015) |
| " The Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension (ACCOMPLISH) trial showed that the combination of benazepril+amlodipine (B+A) is superior to benazepril+hydrochlorothiazide (B+H) in reducing CV events." | 5.20 | Amlodipine+benazepril is superior to hydrochlorothiazide+benazepril irrespective of baseline pulse pressure: subanalysis of the ACCOMPLISH trial. ( Asp, J; Dahlöf, B; Jamerson, KA; Jia, Y; Kjeldsen, SE; Östergren, J; Skoglund, PH; Svensson, P; Weber, MA; Zappe, DH, 2015) |
| "The clinical data of 24 patients with ischemic stroke in our intensive care unit were analyzed, and received amlodipine or metoprolol for more than 14 days with 24-hour ambulatory blood pressure monitoring." | 5.19 | Effects of different antihypertensive drugs on blood pressure variability in patients with ischemic stroke. ( Hu, WL; Ji, M; Li, SJ, 2014) |
| "This study was conducted to compare the BP-lowering and diurnal BP variation effects of amlodipine and losartan on acute stroke patients." | 5.17 | Comparison of the effects of amlodipine and losartan on blood pressure and diurnal variation in hypertensive stroke patients: a prospective, randomized, double-blind, comparative parallel study. ( Hong, YH; Kwon, HM; Lee, YS; Lim, JS; Nam, H; Shin, JW, 2013) |
| " Therefore, we designed a randomized controlled trial using amlodipine as the base drug of a multi-drug regimen, the Optimal Combination of Effective ANtihypertensives (OCEAN) Study, to determine the drug combination that is most efficacious in the prevention of cardiovascular events, such as stroke." | 5.16 | Optimal Combination of Effective ANtihypertensives (OCEAN) study: a prospective, randomized, open-label, blinded endpoint trial--rationale, design and results of a pilot study in Japan. ( Kageyama, S; Miyakawa, M; Mochizuki, K; Nakayama, M; Ohashi, Y; Saito, I; Saruta, T; Sugawara, M; Ueda, S, 2012) |
| "The Anglo-Scandinavian Cardiac Outcomes Trial Blood Pressure Lowering Arm (ASCOT-BPLA) compared amlodipine-based regimens with atenolol-based regimens in 19 257 patients with hypertension and other vascular risk factors and the Medical Research Council (MRC) trial compared atenolol-based and diuretic-based regimens versus placebo in 4396 hypertensive patients aged 65-74 years." | 5.14 | Effects of beta blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. ( Dahlöf, B; Dobson, JE; Dolan, E; Howard, SC; O'Brien, E; Poulter, NR; Rothwell, PM; Sever, PS, 2010) |
| "There was evidence of pharmacogenetic effects of FGB-455 on stroke, ESRD, and mortality, suggesting that relative to those homozygous for the common allele, variant allele carriers of the FGB gene at position -455 have a better outcome if randomized to lisinopril than chlorthalidone (for mortality and ESRD) or amlodipine (for mortality and stroke)." | 5.14 | Antihypertensive pharmacogenetic effect of fibrinogen-beta variant -455G>A on cardiovascular disease, end-stage renal disease, and mortality: the GenHAT study. ( Arnett, DK; Boerwinkle, E; Davis, BR; Eckfeldt, JH; Ford, CE; Leiendecker-Foster, C; Lynch, AI, 2009) |
| "To compare the cost effectiveness of an amlodipine-based strategy and an atenolol-based strategy in the treatment of hypertension in the UK and Sweden." | 5.13 | Economic evaluation of ASCOT-BPLA: antihypertensive treatment with an amlodipine-based regimen is cost effective compared with an atenolol-based regimen. ( Buxton, M; Dahlöf, B; Jönsson, B; Kahan, T; Lindgren, P; Poulter, NR; Sever, PS; Wedel, H, 2008) |
| "The trial was terminated early due to significant benefits on mortality and stroke associated with the amlodipine-based regimen." | 5.13 | The Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patients with type II diabetes. ( Beevers, G; Caulfield, M; Collins, R; Dahlöf, B; Kjeldsen, SE; Kristinsson, A; McInnes, GT; Mehlsen, J; Nieminen, M; O'Brien, E; Ostergren, J; Poulter, NR; Sever, PS; Wedel, H, 2008) |
| "The risk of myocardial infarction was significantly decreased with an amlodipine-based regimen compared with a non-CCB-based regimen (odds ratio [OR], 0." | 4.90 | Amlodipine and cardiovascular outcomes in hypertensive patients: meta-analysis comparing amlodipine-based versus other antihypertensive therapy. ( Choi, HM; Ko, SK; Lee, HY; Lee, SA; Park, HJ, 2014) |
| "In the present quantitative overview of outcome trials, we investigated the efficacy of amlodipine or angiotensin receptor blockers in the prevention of stroke and myocardial infarction in patients with hypertension, coronary artery disease, or diabetic nephropathy." | 4.84 | Prevention of stroke and myocardial infarction by amlodipine and Angiotensin receptor blockers: a quantitative overview. ( Franklin, SS; Li, Y; Safar, M; Wang, JG, 2007) |
| "Participants with hypertension and ≥3 cardiovascular disease risk factors were randomly allocated to amlodipine- or atenolol-based BP-lowering regimen targeting BP <140/90 mm Hg for 5." | 4.02 | Long-Term Incidence of Stroke and Dementia in ASCOT. ( Godec, T; Gupta, AK; Mackay, J; Rostamian, S; Sever, PS; Whitehouse, A; Whiteley, WN, 2021) |
| " amlodipine in patients with hypertension and different risks of cardiovascular events, followed for a mean of 4." | 3.88 | Blood pressure variability and risk of cardiovascular events and death in patients with hypertension and different baseline risks. ( Berge, E; Hua, TA; Julius, S; Kjeldsen, SE; Liestøl, K; Mancia, G; Mehlum, MH; Parati, G; Rothwell, PM; Weber, MA, 2018) |
| "In newly diagnosed patients with hypertension, lercanidipine was superior to nifedipine in the six-year period when the analyzed endpoint was stroke." | 3.85 | Long-term outcomes of lercanidipine versus other calcium channel blockers in newly diagnosed hypertension: a nationwide cohort study. ( Cheng, KC; Cheng, KH; Cheng, KY; Lai, WT; Lee, CW; Yang, YH, 2017) |
| "The current study investigated the efficacy of losartan and amlodipine in protecting spontaneously hypertensive stroke-prone (SHRSP) rats against the risk of stroke." | 3.83 | Prehypertensive treatment with losartan, however not amlodipine, leads to long-term effects on blood pressure and reduces the risk of stroke in spontaneously hypertensive stroke-prone rats. ( He, D; Lin, J; Zhang, L, 2016) |
| "The aim of this study was to investigate whether there is a genotype-by-treatment interaction in patients experiencing stroke and treated with one of three antihypertensive drugs, that is chlorthalidone, amlodipine, or lisinopril." | 3.80 | Pharmacogenetic effects of 'candidate gene complexes' on stroke in the GenHAT study. ( Arnett, DK; Boerwinkle, E; Davis, BR; Eckfeldt, JH; Ford, CE; Irvin, MR; Sørensen, IF; Sørensen, P; Vazquez, AI, 2014) |
| "The pharmacodynamic analysis end point was clopidogrel on-treatment platelet reactivity (OPR) and the clinical analysis end point was the composite of cardiac death, non-fatal myocardial infarction, ischaemic stroke and stent thrombosis at 12 months post-PCI." | 3.78 | Amlodipine, clopidogrel and CYP3A5 genetic variability: effects on platelet reactivity and clinical outcomes after percutaneous coronary intervention. ( Kang, HJ; Kang, J; Kim, HS; Koo, BK; Lee, HY; Oh, BH; Park, JJ; Park, KW; Park, YB; Yang, HM, 2012) |
| "The vascular protective effects of placebo, candesartan (1 mg kg(-1) per day) monotherapy, candesartan (1 mg kg(-1) per day) and amlodipine (1 mg kg(-1) per day) combination therapy, and candesartan (1 mg kg(-1) per day) and hydrochlorothiazide (HCTZ) (10 mg kg(-1) per day) combination therapy for 2 weeks were compared in stroke-prone, spontaneously hypertensive rats." | 3.77 | Candesartan and amlodipine combination therapy provides powerful vascular protection in stroke-prone spontaneously hypertensive rats. ( Jin, D; Miyazaki, M; Sakonjo, H; Shimosato, T; Takai, S, 2011) |
| " In this study, we investigated whether amlodipine protects against the reduction in bone density in stroke-prone spontaneously hypertensive rats (SHR-sp)." | 3.76 | Protective effect of amlodipine against osteoporosis in stroke-prone spontaneously hypertensive rats. ( Ando, H; Fujimura, A; Ishikawa, E; Liu, Y; Maekawa, T; Motosugi, Y; Tsuruoka, S; Ushijima, K, 2010) |
| "To report a case of angioedema likely associated with amlodipine administration in a patient with a right thalamic hemorrhagic stroke." | 3.75 | Probable amlodipine-induced angioedema. ( Irvine, E; Rabinovich, M; Southward, J, 2009) |
| "To test the effects of atenolol and amlodipine, either alone or in combination, on blood pressure, blood pressure variability (BPV), baroreflex sensitivity (BRS), and the prevalence of stroke in stroke-prone spontaneously hypertensive rats (SHR-SP)." | 3.74 | Effects of combination therapy with atenolol and amlodipine on blood pressure control and stroke prevention in stroke-prone spontaneously hypertensive rats. ( Cai, GJ; Ling, G; Liu, AJ; Liu, JG; Shen, FM; Su, DF, 2007) |
| "The present study examined the levels of Angiotensin II type 1 receptor (AT(1)) and type 2 receptor (AT(2)) in the brain stem and cerebral cortex of the stroke-prone spontaneously hypertensive rat (SHR-sp) after long-term treatment with three types of antihypertensive drugs: valsartan, enalapril, and amlodipine." | 3.74 | Decreased expression of angiotensin II type 1 and type 2 receptors in the brain after long-term administration of antihypertensive drugs in stroke-prone spontaneously hypertensive rat. ( Asai, S; Ishikawa, K; Nishida, Y; Sugahara-Kobayashi, M; Takahashi, Y, 2008) |
| "This study investigated the effects of amlodipine, an L-type calcium channel blocker, on stroke size after focal brain ischemia in apolipoprotein E-deficient (ApoE KO) mice." | 3.73 | Amlodipine treatment reduces stroke size in apolipoprotein E-deficient mice. ( Chen, R; Horiuchi, M; Ide, A; Iwai, M; Iwanami, J; Mogi, M; Tsukuda, K; Yoshii, T, 2006) |
| "Excess salt, via oxidative stress, accelerates stroke, and angiotensin II, via AT1 receptor, plays a pivotal role in brain superoxide production of SHRSP by excess salt." | 3.73 | Critical role of angiotensin II in excess salt-induced brain oxidative stress of stroke-prone spontaneously hypertensive rats. ( Ioroi, T; Iwao, H; Izumi, Y; Izumiya, Y; Kim-Mitsuyama, S; Tanaka, T; Wanibuchi, H; Yamamoto, E; Zhan, Y, 2005) |
| "We studied the early pathophysiological response of lenticulostriate arterioles in rats in three models of human conditions associated with stroke: (a) chronic angiotensin II-hypertension; (b) chronic nicotine administration; (c) oxidative endothelial injury." | 3.72 | Early pathophysiological changes in cerebral vessels predisposing to stroke. ( Gerzanich, V; Ivanova, S; Simard, JM, 2003) |
| "To determine the effects of the angiotensin II receptor antagonist irbesartan, the calcium-channel blocker amlodipine, and hydrochlorothiazide/hydralazine on superoxide, NAD(P)H oxidase and nitric oxide bioavailability in spontaneously hypertensive stroke-prone rats (SHRSP)." | 3.71 | Irbesartan lowers superoxide levels and increases nitric oxide bioavailability in blood vessels from spontaneously hypertensive stroke-prone rats. ( Brosnan, MJ; Dominiczak, AF; Graham, D; Hamilton, CA; Jardine, E; Lygate, CA, 2002) |
| " Perindopril, candesartan cilexetil, or amlodipine alone or the combination of low doses of each agent was administered orally to stroke-prone spontaneously hypertensive rats (SHRSP) for 4 weeks to compare the hypotensive or cardiovascular effects." | 3.70 | Cardiovascular effects of combination of perindopril, candesartan, and amlodipine in hypertensive rats. ( Iwao, H; Izumi, Y; Kim, S; Zhan, Y, 2000) |
| "2 years in the VALUE trial (Valsartan Antihypertensive Long-Term Use Evaluation)." | 2.94 | Blood Pressure-Lowering Profiles and Clinical Effects of Angiotensin Receptor Blockers Versus Calcium Channel Blockers. ( Berge, E; Julius, S; Kjeldsen, SE; Liestøl, K; Mancia, G; Mehlum, MH; Parati, G; Rothwell, PM; Weber, MA; Wyller, TB, 2020) |
| " In the prospective Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial, patients were randomized to valsartan or amlodipine regimens and followed for 4." | 2.82 | No evidence for a J-shaped curve in treated hypertensive patients with increased cardiovascular risk: The VALUE trial. ( Bangalore, S; Berge, E; Holzhauer, B; Hua, TA; Julius, S; Kjeldsen, SE; Mancia, G; Messerli, FH; Weber, MA; Zanchetti, A; Zappe, D, 2016) |
| "The primary composite outcomes were sudden cardiac death, acute myocardial infarction, stroke, coronary revascularization, or hospitalization for heart failure." | 2.78 | Effects of valsartan versus amlodipine in diabetic hypertensive patients with or without previous cardiovascular disease. ( Kondo, T; Maeda, K; Matsushita, K; Muramatsu, T; Murohara, T; Nagahiro, T; Shintani, S; Yamashita, K, 2013) |
| "We conducted retrospective analyses of the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) data." | 2.77 | Cardiovascular outcomes in hypertensive patients: comparing single-agent therapy with combination therapy. ( Brunner, HR; Hua, TA; Jia, Y; Julius, S; Kjeldsen, SE; Mancia, G; McInnes, GT; Schork, A; Weber, MA; Zanchetti, A; Zappe, DH, 2012) |
| "In olmesartan-treated patients, CBF significantly increased in the affected and unaffected hemispheres, and CRC increased significantly in the affected hemisphere." | 2.74 | Benefits of the angiotensin II receptor antagonist olmesartan in controlling hypertension and cerebral hemodynamics after stroke. ( Kawahira, K; Matsumoto, S; Miyata, R; Shimodozono, M, 2009) |
| " Although the overall goal of these drugs remains the blockade of RAS activation, their individual targets in this system vary and may substantially influence the clinical benefit derived from the long term use of these substances." | 2.45 | Angiotensin II type 1 receptor blockade: high hopes sent back to reality? ( Divchev, D; Grothusen, A; Luchtefeld, M; Schieffer, B, 2009) |
| "amlodipine was associated with lower BPV than other CCBs for both hypertensive patients and hypertensive patients with comorbidity." | 1.48 | Comparison of amlodipine versus other calcium channel blockers on blood pressure variability in hypertensive patients in China: a retrospective propensity score-matched analysis. ( Dong, P; Li, L; Lin, Y; Liu, D; Xie, X; Yang, J; Zhang, L, 2018) |
| "Hypertension is considered to be the most important risk factor for stroke, and all forms of hypertension are associated with an increased risk of both ischemic and haemorrhagic stroke." | 1.43 | Significance of BP Control in Reducing Stroke Events: Role of Amlodipine in an Indian Perspective. ( Muruganathan, A; Tiwaskar, M, 2016) |
| "Prehypertension has been associated with adverse cerebrovascular events and brain damage." | 1.40 | Long-term prehypertension treatment with losartan effectively prevents brain damage and stroke in stroke-prone spontaneously hypertensive rats. ( He, DH; Lin, JX; Lin, LM; Ning, RB; Wang, HJ; Xu, CS; Zhang, LM, 2014) |
| "Delirium is a neuropsychiatric syndrome recognized as a marker for increased health care costs, morbidity, mortality, and institutionalization that often complicates acute physical illness in elderly people." | 1.38 | Amlodipine-induced delirium in a patient with ischemic stroke. ( Dikici, S; Kocaman, G; Kocer, A; Ozdem, S, 2012) |
| "Ischemic stroke is a major neurologic disorder and a leading cause of disability and death in the world." | 1.37 | Protection against ischemic stroke damage by synergistic treatment with amlodipine plus atorvastatin in Zucker metabolic rat. ( Abe, K; Deguchi, K; Deguchi, S; Ikeda, Y; Kawai, H; Kurata, T; Matsuura, T; Ohta, Y; Omote, Y; Yamashita, T, 2011) |
| "Stroke is a major neurologic disorder and a leading cause of death in the world." | 1.37 | Synergistic benefit of combined amlodipine plus atorvastatin on neuronal damage after stroke in Zucker metabolic rat. ( Abe, K; Deguchi, K; Deguchi, S; Ikeda, Y; Kawai, H; Liu, N; Liu, W; Matsuura, T; Ohta, Y; Shang, J; Tian, F; Yamashita, T; Zhang, X, 2011) |
| "Amlodipine is a dihydropyridine calcium channel blocker that is widely used for the treatment of hypertensive patients and has an antioxidant effect on vessels in vitro." | 1.33 | Amlodipine-induced reduction of oxidative stress in the brain is associated with sympatho-inhibitory effects in stroke-prone spontaneously hypertensive rats. ( Hirooka, Y; Ito, K; Kimura, Y; Nozoe, M; Sagara, Y; Sunagawa, K, 2006) |
| "Cerebral damage (cerebral edema and blood-brain barrier integrity) was investigated with magnetic resonance imaging twice a week." | 1.31 | Reduction of cerebral injury in stroke-prone spontaneously hypertensive rats by amlodipine. ( Blezer, E; Goldschmeding, R; Joles, J; Koomans, H; Nicolay, K, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 31 (41.33) | 29.6817 |
| 2010's | 40 (53.33) | 24.3611 |
| 2020's | 4 (5.33) | 2.80 |
| Authors | Studies |
|---|---|
| Itoga, NK | 1 |
| Tawfik, DS | 1 |
| Montez-Rath, ME | 1 |
| Chang, TI | 1 |
| Bao, H | 1 |
| Huang, X | 1 |
| Li, P | 1 |
| Sheng, C | 1 |
| Zhang, J | 1 |
| Wang, Z | 1 |
| Song, D | 1 |
| Hu, L | 1 |
| Ding, C | 1 |
| Cheng, Z | 1 |
| Yao, C | 1 |
| Chen, G | 1 |
| Cui, Y | 1 |
| Qin, X | 1 |
| Tang, G | 1 |
| Wang, X | 1 |
| Huo, Y | 1 |
| Cheng, X | 1 |
| Wang, J | 1 |
| Navia, V | 1 |
| Riveros, R | 1 |
| Brunser, A | 1 |
| Mehlum, MH | 2 |
| Liestøl, K | 2 |
| Kjeldsen, SE | 6 |
| Wyller, TB | 1 |
| Julius, S | 4 |
| Rothwell, PM | 3 |
| Mancia, G | 4 |
| Parati, G | 2 |
| Weber, MA | 6 |
| Berge, E | 3 |
| Whiteley, WN | 1 |
| Gupta, AK | 2 |
| Godec, T | 1 |
| Rostamian, S | 1 |
| Whitehouse, A | 1 |
| Mackay, J | 1 |
| Sever, PS | 4 |
| Hua, TA | 3 |
| Zhang, L | 2 |
| Yang, J | 1 |
| Li, L | 1 |
| Liu, D | 1 |
| Xie, X | 1 |
| Dong, P | 1 |
| Lin, Y | 1 |
| Haywood, LJ | 3 |
| Davis, BR | 7 |
| Piller, LB | 2 |
| Simpson, LM | 1 |
| Ghosh, A | 1 |
| Einhorn, PT | 1 |
| Ford, CE | 6 |
| Probstfield, JL | 3 |
| Soliman, EZ | 1 |
| Wright, JT | 3 |
| Kolos, I | 1 |
| Loukianov, M | 1 |
| Dupik, N | 1 |
| Boytsov, S | 1 |
| Deev, A | 1 |
| Oparil, S | 3 |
| Cushman, WC | 2 |
| Furberg, CD | 1 |
| Habib, GB | 2 |
| Margolis, K | 1 |
| Whelton, PK | 2 |
| Yamashita, K | 1 |
| Kondo, T | 1 |
| Muramatsu, T | 1 |
| Matsushita, K | 1 |
| Nagahiro, T | 1 |
| Maeda, K | 1 |
| Shintani, S | 1 |
| Murohara, T | 1 |
| Kwon, HM | 1 |
| Shin, JW | 1 |
| Lim, JS | 1 |
| Hong, YH | 1 |
| Lee, YS | 1 |
| Nam, H | 1 |
| He, DH | 1 |
| Zhang, LM | 1 |
| Lin, LM | 1 |
| Ning, RB | 1 |
| Wang, HJ | 1 |
| Xu, CS | 1 |
| Lin, JX | 1 |
| Park, CG | 1 |
| Lee, SA | 1 |
| Choi, HM | 1 |
| Park, HJ | 1 |
| Ko, SK | 1 |
| Lee, HY | 2 |
| Sørensen, IF | 1 |
| Vazquez, AI | 1 |
| Irvin, MR | 1 |
| Sørensen, P | 1 |
| Boerwinkle, E | 3 |
| Eckfeldt, JH | 3 |
| Arnett, DK | 3 |
| Ji, M | 1 |
| Li, SJ | 1 |
| Hu, WL | 1 |
| Cao, TS | 1 |
| Huynh, VM | 1 |
| Tran, VH | 1 |
| Yamal, JM | 1 |
| Alderman, MH | 1 |
| Calhoun, DA | 1 |
| Fendley, HF | 1 |
| Franklin, SS | 2 |
| Pressel, SL | 1 |
| Sastrasinh, S | 1 |
| Skoglund, PH | 1 |
| Svensson, P | 1 |
| Asp, J | 1 |
| Dahlöf, B | 5 |
| Jamerson, KA | 1 |
| Jia, Y | 2 |
| Zappe, DH | 2 |
| Östergren, J | 2 |
| Hasegawa, Y | 1 |
| Nakagawa, T | 1 |
| Uekawa, K | 1 |
| Ma, M | 1 |
| Lin, B | 1 |
| Kusaka, H | 1 |
| Katayama, T | 1 |
| Sueta, D | 1 |
| Toyama, K | 1 |
| Koibuchi, N | 1 |
| Kim-Mitsuyama, S | 2 |
| Bangalore, S | 1 |
| Messerli, FH | 1 |
| Holzhauer, B | 1 |
| Zappe, D | 1 |
| Zanchetti, A | 2 |
| He, D | 1 |
| Lin, J | 1 |
| Wald, NJ | 1 |
| Luteijn, JM | 1 |
| Morris, JK | 1 |
| Taylor, D | 1 |
| Oppenheimer, P | 1 |
| Muruganathan, A | 1 |
| Tiwaskar, M | 1 |
| Cheng, KH | 1 |
| Cheng, KC | 1 |
| Cheng, KY | 1 |
| Yang, YH | 1 |
| Lee, CW | 1 |
| Lai, WT | 1 |
| Poulter, NR | 3 |
| Wedel, H | 2 |
| Beevers, G | 1 |
| Caulfield, M | 1 |
| Collins, R | 1 |
| Kristinsson, A | 1 |
| McInnes, GT | 2 |
| Mehlsen, J | 1 |
| Nieminen, M | 1 |
| O'Brien, E | 2 |
| Southward, J | 1 |
| Irvine, E | 1 |
| Rabinovich, M | 1 |
| Lynch, AI | 2 |
| Leiendecker-Foster, C | 2 |
| Matsumoto, S | 1 |
| Shimodozono, M | 1 |
| Miyata, R | 1 |
| Kawahira, K | 1 |
| Grothusen, A | 1 |
| Divchev, D | 1 |
| Luchtefeld, M | 1 |
| Schieffer, B | 1 |
| Ushijima, K | 1 |
| Liu, Y | 1 |
| Maekawa, T | 1 |
| Ishikawa, E | 1 |
| Motosugi, Y | 1 |
| Ando, H | 1 |
| Tsuruoka, S | 1 |
| Fujimura, A | 1 |
| Howard, SC | 1 |
| Dolan, E | 1 |
| Dobson, JE | 1 |
| Kawai, H | 2 |
| Deguchi, S | 2 |
| Deguchi, K | 2 |
| Yamashita, T | 2 |
| Ohta, Y | 2 |
| Shang, J | 1 |
| Tian, F | 1 |
| Zhang, X | 2 |
| Liu, N | 1 |
| Liu, W | 1 |
| Ikeda, Y | 2 |
| Matsuura, T | 2 |
| Abe, K | 2 |
| Takai, S | 1 |
| Jin, D | 1 |
| Shimosato, T | 1 |
| Sakonjo, H | 1 |
| Miyazaki, M | 1 |
| Omote, Y | 1 |
| Kurata, T | 1 |
| Holtkamp, FA | 1 |
| de Zeeuw, D | 1 |
| de Graeff, PA | 1 |
| Laverman, GD | 1 |
| Berl, T | 1 |
| Remuzzi, G | 1 |
| Packham, D | 1 |
| Lewis, JB | 1 |
| Parving, HH | 1 |
| Lambers Heerspink, HJ | 1 |
| Takagi, H | 2 |
| Umemoto, T | 2 |
| Takano, H | 1 |
| Hasegawa, H | 1 |
| Narumi, H | 1 |
| Shindo, S | 1 |
| Mizuma, H | 1 |
| Kuwabara, Y | 1 |
| Kobayashi, Y | 1 |
| Komuro, I | 1 |
| Kageyama, S | 1 |
| Ueda, S | 1 |
| Mochizuki, K | 1 |
| Miyakawa, M | 1 |
| Sugawara, M | 1 |
| Nakayama, M | 1 |
| Ohashi, Y | 1 |
| Saito, I | 1 |
| Saruta, T | 1 |
| Rahman, M | 1 |
| Cutler, JA | 1 |
| Barzilay, JI | 1 |
| Brown, CD | 1 |
| Colon, PJ | 1 |
| Fine, LJ | 1 |
| Grimm, RH | 1 |
| Baimbridge, C | 1 |
| Henriquez, MA | 1 |
| Ilamaythi, E | 1 |
| Preston, R | 1 |
| Dikici, S | 1 |
| Kocaman, G | 1 |
| Ozdem, S | 1 |
| Kocer, A | 1 |
| Park, KW | 1 |
| Kang, J | 1 |
| Park, JJ | 1 |
| Yang, HM | 1 |
| Kang, HJ | 1 |
| Koo, BK | 1 |
| Oh, BH | 1 |
| Park, YB | 1 |
| Kim, HS | 1 |
| Brunner, HR | 1 |
| Schork, A | 1 |
| Spence, JD | 1 |
| Blezer, E | 1 |
| Nicolay, K | 1 |
| Goldschmeding, R | 1 |
| Koomans, H | 1 |
| Joles, J | 1 |
| Scott, I | 1 |
| Stowasser, M | 1 |
| Düsing, R | 1 |
| Nenciu, A | 1 |
| Stefan, C | 1 |
| Cucea, R | 1 |
| Neacşu, A | 1 |
| Balaş, M | 1 |
| Muşat, A | 1 |
| Dachin, L | 1 |
| Sîrbu, C | 1 |
| Rahn, KH | 2 |
| Gerzanich, V | 1 |
| Ivanova, S | 1 |
| Simard, JM | 1 |
| Yamagata, K | 1 |
| Ichinose, S | 1 |
| Tagami, M | 1 |
| Kuwajima, I | 1 |
| Yamamoto, E | 1 |
| Tanaka, T | 1 |
| Zhan, Y | 2 |
| Izumi, Y | 2 |
| Izumiya, Y | 1 |
| Ioroi, T | 1 |
| Wanibuchi, H | 1 |
| Iwao, H | 2 |
| Umemoto, S | 1 |
| Tanaka, M | 1 |
| Kawahara, S | 1 |
| Kubo, M | 1 |
| Umeji, K | 1 |
| Hashimoto, R | 1 |
| Matsuzaki, M | 1 |
| Rafii, MS | 1 |
| Koenig, M | 1 |
| Ziai, WC | 1 |
| Strauss, MH | 1 |
| Verma, S | 1 |
| Hirooka, Y | 1 |
| Kimura, Y | 1 |
| Nozoe, M | 1 |
| Sagara, Y | 1 |
| Ito, K | 1 |
| Sunagawa, K | 1 |
| Fukui, T | 1 |
| Mogi, M | 1 |
| Iwai, M | 1 |
| Chen, R | 1 |
| Iwanami, J | 1 |
| Ide, A | 1 |
| Tsukuda, K | 1 |
| Yoshii, T | 1 |
| Horiuchi, M | 1 |
| Bakris, GL | 1 |
| Pitt, B | 1 |
| Velazquez, E | 1 |
| Gupte, J | 1 |
| Lefkowitz, M | 1 |
| Hester, A | 1 |
| Shi, V | 1 |
| Weir, M | 1 |
| Kjeldsen, S | 1 |
| Massie, B | 1 |
| Nesbitt, S | 1 |
| Ofili, E | 1 |
| Jamerson, K | 1 |
| Wang, JG | 1 |
| Li, Y | 1 |
| Safar, M | 1 |
| Balligand, JL | 1 |
| Godfraind, T | 1 |
| Lindgren, P | 1 |
| Buxton, M | 1 |
| Kahan, T | 1 |
| Jönsson, B | 1 |
| Ling, G | 1 |
| Liu, AJ | 1 |
| Shen, FM | 1 |
| Cai, GJ | 1 |
| Liu, JG | 1 |
| Su, DF | 1 |
| Umasankar, U | 1 |
| Carroll, TJ | 1 |
| Famuboni, A | 1 |
| Patel, MD | 1 |
| Starke, ID | 1 |
| Nishida, Y | 1 |
| Takahashi, Y | 1 |
| Sugahara-Kobayashi, M | 1 |
| Ishikawa, K | 1 |
| Asai, S | 1 |
| Kim, S | 1 |
| Brosnan, MJ | 1 |
| Hamilton, CA | 1 |
| Graham, D | 1 |
| Lygate, CA | 1 |
| Jardine, E | 1 |
| Dominiczak, AF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Carotid Endarterectomy Versus Optimal Medical Treatment of Asymptomatic High Grade Carotid Artery Stenosis[NCT00805311] | Phase 4 | 400 participants (Actual) | Interventional | 2009-04-30 | Terminated (stopped due to Due to the clear advantage of carotid endarterectomy) | ||
| [NCT00000542] | Phase 3 | 0 participants | Interventional | 1993-08-31 | Completed | ||
| The Novel Antihypertensive Goal Of hYpertension With diAbetes - Hypertensive Events and ARb Treatment (NAGOYA-HEART) Study[NCT00129233] | Phase 4 | 1,150 participants (Actual) | Interventional | 2004-10-31 | Completed | ||
| Comparison of the Effects of Amlodipine and Losartan on Blood Pressure and Diurnal Variation in Hypertensive Stroke Patients[NCT01830517] | Phase 4 | 84 participants (Actual) | Interventional | 2007-08-31 | Completed | ||
| Effect of Combined Antihypertensive Therapy on Blood Pressure and Sexual Function in Patients With Essential Hypertension[NCT01238705] | Phase 4 | 280 participants (Anticipated) | Interventional | 2008-04-30 | Recruiting | ||
| Pharmacological Association of the Angiotensin-Converting Enzyme Insertion/Deletion Polymorphism on Blood Pressure and Cardiovascular Risk in Relation to Anti-hypertensive Treatment[NCT00006294] | 37,939 participants (Actual) | Observational | 1999-09-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 reviews available for amlodipine and Stroke
| Article | Year |
|---|---|
Amlodipine and cardiovascular outcomes in hypertensive patients: meta-analysis comparing amlodipine-based versus other antihypertensive therapy.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Chi-Square Distributi | 2014 |
Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antih | 2009 |
Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin Receptor Antagonists; Biphenyl Compounds; Blood Pressure; | 2011 |
Revisiting evidence of blood pressure-dependent and independent effects of amlodipine on the risk of stroke.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Humans; Hypertension; | 2011 |
[Recent intervention studies with antihypertensive drugs and their influence on guidelines].
Topics: Adrenergic beta-Antagonists; Aged; Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Convert | 2003 |
[ALLHAT trial--antithesis to the overuse of vasodilating antihypertensive drugs].
Topics: Adrenergic alpha-Antagonists; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypert | 2004 |
[CASE-J].
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensiv | 2006 |
Prevention of stroke and myocardial infarction by amlodipine and Angiotensin receptor blockers: a quantitative overview.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Coronary Artery | 2007 |
25 trials available for amlodipine and Stroke
| Article | Year |
|---|---|
Combined use of amlodipine and folic acid are significantly more efficacious than amlodipine alone in lowering plasma homocysteine and blood pressure among hypertensive patients with hyperhomocysteinemia and intolerance to ACEI: A multicenter, randomized,
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Double-Blind Method; Folic Aci | 2023 |
Blood Pressure-Lowering Profiles and Clinical Effects of Angiotensin Receptor Blockers Versus Calcium Channel Blockers.
Topics: Amlodipine; Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Blood Pre | 2020 |
Risk Factors Influencing Outcomes of Atrial Fibrillation in ALLHAT.
Topics: Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Atrial Fibrillation; Atrial Flutter; C | 2018 |
Optimal medical treatment versus carotid endarterectomy: the rationale and design of the Aggressive Medical Treatment Evaluation for Asymptomatic Carotid Artery Stenosis (AMTEC) study.
Topics: Amlodipine; Antihypertensive Agents; Aspirin; Carotid Stenosis; Combined Modality Therapy; Endartere | 2015 |
Mortality and morbidity during and after Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: results by sex.
Topics: Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; Chlorthalido | 2013 |
Effects of valsartan versus amlodipine in diabetic hypertensive patients with or without previous cardiovascular disease.
Topics: Aged; Amlodipine; Antihypertensive Agents; Cardiovascular Diseases; Case-Control Studies; Death, Sud | 2013 |
Comparison of the effects of amlodipine and losartan on blood pressure and diurnal variation in hypertensive stroke patients: a prospective, randomized, double-blind, comparative parallel study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Ci | 2013 |
Effects of different antihypertensive drugs on blood pressure variability in patients with ischemic stroke.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Blood Pre | 2014 |
Effects of lercanidipine versus amlodipine in hypertensive patients with cerebral ischemic stroke.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Brain Ischemia; Di | 2015 |
Stroke outcomes among participants randomized to chlorthalidone, amlodipine or lisinopril in ALLHAT.
Topics: Age Factors; Aged; Amlodipine; Cause of Death; Chlorthalidone; Confidence Intervals; Dose-Response R | 2014 |
Amlodipine+benazepril is superior to hydrochlorothiazide+benazepril irrespective of baseline pulse pressure: subanalysis of the ACCOMPLISH trial.
Topics: Aged; Amlodipine; Antihypertensive Agents; Benzazepines; Blood Pressure; Double-Blind Method; Drug T | 2015 |
No evidence for a J-shaped curve in treated hypertensive patients with increased cardiovascular risk: The VALUE trial.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Determination; Coronary Ar | 2016 |
The Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patients with type II diabetes.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; | 2008 |
Antihypertensive pharmacogenetic effect of fibrinogen-beta variant -455G>A on cardiovascular disease, end-stage renal disease, and mortality: the GenHAT study.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel | 2009 |
Benefits of the angiotensin II receptor antagonist olmesartan in controlling hypertension and cerebral hemodynamics after stroke.
Topics: Acetazolamide; Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Ag | 2009 |
Effects of beta blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amlodipine; Antihypertensive Agents; Atenolol; Blood Press | 2010 |
Effects of valsartan and amlodipine on home blood pressure and cardiovascular events in Japanese hypertensive patients: a subanalysis of the VART.
Topics: Aged; Albuminuria; Amlodipine; Angina Pectoris; Antihypertensive Agents; Asian People; Blood Pressur | 2012 |
Optimal Combination of Effective ANtihypertensives (OCEAN) study: a prospective, randomized, open-label, blinded endpoint trial--rationale, design and results of a pilot study in Japan.
Topics: Adrenergic beta-Antagonists; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin- | 2012 |
Pharmacogenetic association of NOS3 variants with cardiovascular disease in patients with hypertension: the GenHAT study.
Topics: Aged; Alleles; Amlodipine; Antihypertensive Agents; Cardiovascular Diseases; Chlorthalidone; Double- | 2012 |
Pharmacogenetic association of NOS3 variants with cardiovascular disease in patients with hypertension: the GenHAT study.
Topics: Aged; Alleles; Amlodipine; Antihypertensive Agents; Cardiovascular Diseases; Chlorthalidone; Double- | 2012 |
Pharmacogenetic association of NOS3 variants with cardiovascular disease in patients with hypertension: the GenHAT study.
Topics: Aged; Alleles; Amlodipine; Antihypertensive Agents; Cardiovascular Diseases; Chlorthalidone; Double- | 2012 |
Pharmacogenetic association of NOS3 variants with cardiovascular disease in patients with hypertension: the GenHAT study.
Topics: Aged; Alleles; Amlodipine; Antihypertensive Agents; Cardiovascular Diseases; Chlorthalidone; Double- | 2012 |
Long-term renal and cardiovascular outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants by baseline estimated GFR.
Topics: Amlodipine; Antihypertensive Agents; Canada; Chlorthalidone; Chronic Disease; Coronary Disease; Doub | 2012 |
Cardiovascular outcomes in hypertensive patients: comparing single-agent therapy with combination therapy.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Double-Blind Met | 2012 |
Are thiazide diuretics preferred as first-line therapy for hypertension? An appraisal of The Antihypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Aged; Amlodipine; Benzothiadiazines; Blood Chemical Analysis; Chlorthalidone; Diuretics; Dose-Respon | 2003 |
MOSES raises questions.
Topics: Acrylates; Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; Data Interpretation, Stati | 2006 |
Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: a hypertensive population at high cardiovascular risk.
Topics: Aged; Amlodipine; Antihypertensive Agents; Benzazepines; Body Mass Index; Diabetes Mellitus, Type 2; | 2007 |
Economic evaluation of ASCOT-BPLA: antihypertensive treatment with an amlodipine-based regimen is cost effective compared with an atenolol-based regimen.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Atenolol; Cost-Benefit Analysis; Diabetes Mellitus | 2008 |
42 other studies available for amlodipine and Stroke
| Article | Year |
|---|---|
Contributions of Systolic and Diastolic Blood Pressures to Cardiovascular Outcomes in the ALLHAT Study.
Topics: Aged; Amlodipine; Blood Pressure; Blood Pressure Determination; Cardiovascular Diseases; Chlorthalid | 2021 |
[Intravenous thrombolysis after reversion of acenocoumarol anticoagulation. Report of one case].
Topics: Acenocoumarol; Administration, Intravenous; Aged, 80 and over; Amlodipine; Humans; Infarction, Middl | 2019 |
Long-Term Incidence of Stroke and Dementia in ASCOT.
Topics: Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atenolol; Atorvastatin; Cholest | 2021 |
Blood pressure variability and risk of cardiovascular events and death in patients with hypertension and different baseline risks.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Female; Heart Failure; Humans; Hypertensi | 2018 |
Comparison of amlodipine versus other calcium channel blockers on blood pressure variability in hypertensive patients in China: a retrospective propensity score-matched analysis.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; China; Cohort S | 2018 |
Long-term prehypertension treatment with losartan effectively prevents brain damage and stroke in stroke-prone spontaneously hypertensive rats.
Topics: Aldosterone; Amlodipine; Angiotensin II; Animals; Apoptosis; Blood Pressure; Brain; Hypertension; Lo | 2014 |
Is amlodipine more cardioprotective than other antihypertensive drug classes?
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Heart Failure; Humans | 2014 |
Pharmacogenetic effects of 'candidate gene complexes' on stroke in the GenHAT study.
Topics: Aged; Amlodipine; Chlorthalidone; Female; Genotype; Humans; Lisinopril; Male; Middle Aged; Pharmacog | 2014 |
Therapy with the Combination of Amlodipine and Irbesartan Has Persistent Preventative Effects on Stroke Onset Associated with BDNF Preservation on Cerebral Vessels in Hypertensive Rats.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Blood Pressure; Bl | 2016 |
Prehypertensive treatment with losartan, however not amlodipine, leads to long-term effects on blood pressure and reduces the risk of stroke in spontaneously hypertensive stroke-prone rats.
Topics: Amlodipine; Animals; Blood Pressure; Gene Expression Regulation; Humans; Hypertension; Losartan; Mal | 2016 |
Cost-benefit analysis of the polypill in the primary prevention of myocardial infarction and stroke.
Topics: Aged; Aged, 80 and over; Amlodipine; Aspirin; Cardiovascular Agents; Case-Control Studies; Cohort St | 2016 |
Significance of BP Control in Reducing Stroke Events: Role of Amlodipine in an Indian Perspective.
Topics: Amlodipine; Antihypertensive Agents; Drug Therapy, Combination; Humans; Hypertension; India; Stroke | 2016 |
Long-term outcomes of lercanidipine versus other calcium channel blockers in newly diagnosed hypertension: a nationwide cohort study.
Topics: Adolescent; Adult; Aged; Amlodipine; Blood Pressure; Calcium Channel Blockers; Cohort Studies; Dihyd | 2017 |
Probable amlodipine-induced angioedema.
Topics: Amlodipine; Angioedema; Calcium Channel Blockers; Cerebral Hemorrhage; Female; Humans; Middle Aged; | 2009 |
Protective effect of amlodipine against osteoporosis in stroke-prone spontaneously hypertensive rats.
Topics: Administration, Oral; Amlodipine; Animals; Antihypertensive Agents; Blood Pressure; Bone Density; Ca | 2010 |
Synergistic benefit of combined amlodipine plus atorvastatin on neuronal damage after stroke in Zucker metabolic rat.
Topics: Amlodipine; Animals; Anticholesteremic Agents; Atorvastatin; Calcium Channel Blockers; Drug Synergis | 2011 |
What your blood pressure isn't revealing.
Topics: Adrenergic beta-Antagonists; American Heart Association; Amlodipine; Anti-Arrhythmia Agents; Antihyp | 2010 |
Candesartan and amlodipine combination therapy provides powerful vascular protection in stroke-prone spontaneously hypertensive rats.
Topics: Acetylcholine; Amlodipine; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blo | 2011 |
Protection against ischemic stroke damage by synergistic treatment with amlodipine plus atorvastatin in Zucker metabolic rat.
Topics: Amlodipine; Animals; Atorvastatin; Brain Ischemia; Calcium Channel Blockers; Disease Models, Animal; | 2011 |
Blood pressure-dependent and independent effects of amlodipine and angiotensin receptor blockers on the risk of stroke.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Calcium Channel Blockers; Human | 2011 |
[Antihypertensive therapy in routine practice: fixed or free combination? Fixed combination scores with better prognosis].
Topics: Amlodipine; Amlodipine, Valsartan Drug Combination; Antihypertensive Agents; Drug Combinations; Huma | 2011 |
Amlodipine-induced delirium in a patient with ischemic stroke.
Topics: Amlodipine; Calcium Channel Blockers; Delirium; Humans; Ischemia; Male; Middle Aged; Stroke | 2012 |
Amlodipine, clopidogrel and CYP3A5 genetic variability: effects on platelet reactivity and clinical outcomes after percutaneous coronary intervention.
Topics: Aged; Amlodipine; Angioplasty, Balloon, Coronary; Clopidogrel; Cytochrome P-450 CYP3A; Drug Interact | 2012 |
Asymptomatic carotid stenosis.
Topics: Aged; Amlodipine; Anticholesteremic Agents; Aspirin; Asymptomatic Diseases; Atorvastatin; Azetidines | 2013 |
Reduction of cerebral injury in stroke-prone spontaneously hypertensive rats by amlodipine.
Topics: Amlodipine; Animals; Antihypertensive Agents; Blood Pressure; Brain Edema; Hypertension; Male; Rats; | 2002 |
[The new (old) knowledge in primary prevention of stroke. It depends on lowering of blood pressure].
Topics: Adrenergic alpha-Antagonists; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2003 |
[Visual fields defects in cerebral hemorrhagic vascular accident].
Topics: Aged; Amlodipine; Antihypertensive Agents; Aphakia; Drug Therapy, Combination; Enalapril; Female; He | 2003 |
Early pathophysiological changes in cerebral vessels predisposing to stroke.
Topics: Amlodipine; Angiotensin II; Animals; Arterioles; Benzylamines; Brain; Calcium Channel Blockers; Calc | 2003 |
Amlodipine and carvedilol prevent cytotoxicity in cortical neurons isolated from stroke-prone spontaneously hypertensive rats.
Topics: Amlodipine; Animals; Antioxidants; Carbazoles; Carvedilol; Cell Death; Cell Hypoxia; Cells, Cultured | 2004 |
Adult hypertension: reducing cardiovascular morbidity and mortality.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Alcohol Drinking | 2005 |
Critical role of angiotensin II in excess salt-induced brain oxidative stress of stroke-prone spontaneously hypertensive rats.
Topics: Amlodipine; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphen | 2005 |
Calcium antagonist reduces oxidative stress by upregulating Cu/Zn superoxide dismutase in stroke-prone spontaneously hypertensive rats.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Animals; Calcium Channel Blockers; Coronary Ve | 2004 |
Orolingual angioedema associated with ACE inhibitor use after rtPA treatment of acute stroke.
Topics: Acute Disease; Amlodipine; Angioedema; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Dexam | 2005 |
Amlodipine-induced reduction of oxidative stress in the brain is associated with sympatho-inhibitory effects in stroke-prone spontaneously hypertensive rats.
Topics: Amlodipine; Animals; Blood Pressure; Brain Chemistry; Calcium Channel Blockers; Cisterna Magna; Elec | 2006 |
Amlodipine treatment reduces stroke size in apolipoprotein E-deficient mice.
Topics: Amlodipine; Animals; Apolipoproteins E; Brain Ischemia; Calcium Channel Blockers; Cerebrovascular Ci | 2006 |
[Treating essential hypertension. Are beta blockers still first choice?].
Topics: Adrenergic beta-Antagonists; Amlodipine; Antihypertensive Agents; Atenolol; Bendroflumethiazide; Cor | 2007 |
Amlodipine and stroke prevention.
Topics: Amlodipine; Blood Pressure; Calcium Channel Blockers; Circadian Rhythm; Humans; Hypertension; Myocar | 2007 |
Effects of combination therapy with atenolol and amlodipine on blood pressure control and stroke prevention in stroke-prone spontaneously hypertensive rats.
Topics: Amlodipine; Animals; Antihypertensive Agents; Atenolol; Blood Pressure; Drug Synergism; Drug Therapy | 2007 |
Vertebral artery dissection: not a rare cause of stroke in the young.
Topics: Adult; Amlodipine; Anticoagulants; Antihypertensive Agents; Aspirin; Craniocerebral Trauma; Female; | 2008 |
Decreased expression of angiotensin II type 1 and type 2 receptors in the brain after long-term administration of antihypertensive drugs in stroke-prone spontaneously hypertensive rat.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anima | 2008 |
Cardiovascular effects of combination of perindopril, candesartan, and amlodipine in hypertensive rats.
Topics: Adrenergic beta-Antagonists; Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting En | 2000 |
Irbesartan lowers superoxide levels and increases nitric oxide bioavailability in blood vessels from spontaneously hypertensive stroke-prone rats.
Topics: Amlodipine; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Aort | 2002 |